Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update

About this update from Aethlon Medical, Inc.

[{"type":"text","content":"Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32%","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"Conference Call to be Held Today at 4:30 p.m. ET","length":48,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2025, and provided an update on recent developments.","length":352,"tagName":"p"},{"type":"text","content":"Key First Quarter Highlights","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First Cohort Complete in Australian Hemopurifier® cancer trial — all patients treated without device-related serious adverse events and no dose-limiting toxicities observed","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Amended Protocol broadens patient eligibility to allow all treatment regimens that include an anti-PD-1 agent","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Preclinical Data: 98.5% removal of platelet-derived extracellular vesicles (EVs) in simulated 4-hour treatment","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Long COVID Pre-Clinical Research collaboration with UCSF advances, with findings presented at the prestigious Keystone Symposium","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating Expenses Reduced by 31.6%, enhancing operational efficiency","length":69,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":588,"olType":false},{"type":"text","content":"Clinical Progress in Cancer Trial","length":33,"tagName":"p"},{"type":"text","content":"Ongoing progress continues in the Australian Oncology trial evaluating the Hemopurifier in participants with solid tumors that have not responded to anti-PD-1 immunotherapy.","length":173,"tagName":"p"},{"type":"text","content":"Aethlon successfully completed the first treatment cohort in its safety, feasibility, and dose-finding study. This initial cohort involved single Hemopurifier treatments for participants with tumors unresponsive to P...

More updates from Aethlon Medical, Inc.